Rino S Seedor1, Marlana Orloff2. 1. Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA, 19107, USA. 2. Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA, 19107, USA. marlana.orloff@jefferson.edu.
Abstract
PURPOSE OF REVIEW: This study aims to review the clinical experience of melanoma treatments in patients with advanced age. RECENT FINDINGS: During the last decade, the treatment paradigm for melanoma has changed dramatically with the use of checkpoint inhibitors, oncolytic viruses, and targeted therapies. We reviewed both the clinical trial and real-world experience of these therapies in patients of advanced age, and discuss how a personalized approach should be taken for these patients with consideration of incidence and management of side effects. Although special consideration should be taken, immunotherapy, oncolytic viruses, and targeted therapy have shown efficacy and tolerability in older patients with melanoma.
PURPOSE OF REVIEW: This study aims to review the clinical experience of melanoma treatments in patients with advanced age. RECENT FINDINGS: During the last decade, the treatment paradigm for melanoma has changed dramatically with the use of checkpoint inhibitors, oncolytic viruses, and targeted therapies. We reviewed both the clinical trial and real-world experience of these therapies in patients of advanced age, and discuss how a personalized approach should be taken for these patients with consideration of incidence and management of side effects. Although special consideration should be taken, immunotherapy, oncolytic viruses, and targeted therapy have shown efficacy and tolerability in older patients with melanoma.
Authors: Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: W Charles Conway; Mark B Faries; Michael B Nicholl; Alicia M Terando; Edwin C Glass; MyungShin Sim; Donald L Morton Journal: Ann Surg Oncol Date: 2009-03-11 Impact factor: 5.344
Authors: Alfonso Berrocal; Ana Arance; Jose Antonio Lopez Martin; Virtudes Soriano; Eva Muñoz; Lorenzo Alonso; Enrique Espinosa; Pilar Lopez Criado; Javier Valdivia; Salvador Martin Algarra Journal: Melanoma Res Date: 2014-12 Impact factor: 3.599